Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
CNS10-NPC-GDNF for the Treatment of ALS
The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02943850
- Testing
- Stem cell (HPC) implantation, Stereotactic surgical device
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cedars-Sinai Medical Center
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) Gulf War Study
Recently, concern has arisen regarding a possible elevated occurrence of ALS among veterans who served in the Persian Gulf during Operations Desert Shield (August 2, 1990 - January 15, 1991), Desert Storm (January 16, 1991 …
- Trial name
- NCT00007722
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- US Department of Veterans Affairs
Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis
This study will use a magnetic resonance imaging technique called nuclear magnetic spectroscopy (H-MRS) to define the pathology and progression of primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral…
- Conditions
- Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00023075
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
This study will test the hypothesis that noninvasive ventilation (NIV) as prescribed in current medical practice for use in amyotrophic Lateral Sclerosis (ALS) patients fails to deliver adequate breathing support over a night of…
- Trial name
- NCT00537641
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis, Cannabis
EMERALD TRIAL Open Label Extension Study
EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied.
- Conditions
- Amyotrophic Lateral Sclerosis, Cannabis, CBD, Motor Neuron Disease
- Trial name
- EMERALD-OLE (NCT04997954)
- Testing
- MediCabilis CBD oil
- Where
- Australia
- Volunteers
- 7 people
- Sponsor
- Gold Coast Hospital and Health Service
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
EEG and TMS-based Biomarkers of ALS, MS and FTD
The purpose of this observational study is to improve understanding of the biology of why ALS, MS and FTD have different effects on different people and facilitate better measurement of the disease in future drug testing.
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Multiple Sclerosis
- Trial name
- NCT04918251
- Testing
- 128 electrode electroencephalography (EEG), Transcranial magnetic stimulation (TMS)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Amyotrophic Lateral Sclerosis
An Online Mindfulness Intervention for People With ALS and Their Caregivers
The psychological impact of ALS on both patients and caregivers is high and affects their quality of life (QOL). However, there is minimal research about psychological interventions to improve QOL in the ALS scientific…
- Trial name
- NCT03095989
- Testing
- Mindfulness
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Harvard University
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
The purpose of this study is to learn about rates of patient-reported disease progression in patients with motor neuron diseases (amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis, hereditary…
- Conditions
- Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02852278
- Testing
- Web-based Survey
- Volunteers
- 410 people
- Sponsor
- University of South Florida
Amyotrophic Lateral Sclerosis
The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder characterized by amongst others asymmetric muscle weakness, respiratory insufficiency and spasticity.
- Trial name
- NCT00160004
- Testing
- Intensive Controlled Exercise
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
ALS
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
The purpose of this research study is to discover and quantitate the differences in post-translational modifications found in the Cu, Zn superoxide dismutase (SOD1) of patients with amyotrophic lateral sclerosis (ALS) as compared…
- Trial name
- SOD1 (NCT02228915)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Amyotrophic Lateral Sclerosis
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks.
- Trial name
- NCT02450552
- Testing
- Ezogabine
- Where
- 12 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Brian Wainger
Muscle Cramps in Amyotrophic Lateral Sclerosis
Mexiletine for the Treatment of Muscle Cramps in ALS
The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01811355
- Testing
- Mexiletine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bjorn Oskarsson, MD
Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD)
Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases
Neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD) spectrum syndromes, are characterized by the accumulation of insoluble protein aggregates in the central nervous system.
- Conditions
- Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP)
- Trial name
- NCT07567664
- Testing
- 3 Tesla MRI without contrast medium, Blood sample for genetic analysis, Cerebrospinal fluid sampling (CSF)
- Where
- Italy
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Amyotrophic Lateral Sclerosis
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear.
- Trial name
- NCT01592084
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis
Colchicine Effect on Amyotrophic Lateral Sclerosis Patients
The goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder affecting motor…
- Trial name
- CO-ALSII (NCT07813858)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 5 sites in Italy
- Volunteers
- 87 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Amyotrophic Lateral Sclerosis
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.
- Trial name
- NCT04882904
- Testing
- Actimyo°
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Amyotrophic Lateral Sclerosis
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design
- Trial name
- NCT03757351
- Testing
- DNL747
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 15 people
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis (ALS)
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes.
- Trial name
- RAG-21-FUS-ALS (NCT07080801)
- Testing
- RAG-21
- Volunteers
- 6 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis, Movement Disorders
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to…
- Conditions
- Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
- Trial name
- TALSLB (NCT05137665)
- Where
- 12 sites in United States, Colombia and 1 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Target ALS Foundation, Inc.